Supercritical CO2 Coating for Capsule API Uniformity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations face challenges in creating uniform coatings on soft or oblong-shaped capsules, leading to chemical incompatibilities and altered bioavailability of APIs, which are difficult to address with conventional coating methods.
Innovation Solution
A pharmaceutical composition comprising a hard or soft capsule with a first API in a pharmaceutically acceptable vehicle, coated with one or more layers containing a second API, using various coating techniques such as pan coating, fluid bed coating, or spray coating, to achieve uniformity and stability, including additional coatings like immediate release, enteric, or sustained release formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional coating methods are used on soft capsules, then the coating process is simple, but content uniformity is difficult to achieve due to low surface roughness and intrinsic solubility of shell components
Solution Approach 1:
The patent changes the physical-chemical parameters of the coating system by using supercritical carbon dioxide as the coating medium. This supercritical fluid provides enhanced mass transfer properties and allows for precise control of deposition parameters, thereby achieving uniform API distribution on the capsule surface while maintaining processability
Solution Approach 2:
The patent replaces conventional mechanical coating methods (pan coating, spray coating) with a gas-phase deposition process using supercritical fluid. This substitution eliminates the limitations of liquid-based coatings on soft capsule surfaces, enabling uniform coating without compromising capsule integrity or API distribution
2Adaptability or versatility
If APIs are combined in a capsule formulation, then convenience and synergetic effects are achieved, but chemical incompatibilities may result from oxidation-reduction, acid-base, hydrolysis, or combination reactions
Solution Approach 1:
The patent segments the pharmaceutical formulation into distinct spatial zones: APIs are encapsulated within the capsule interior while the capsule exterior surface is coated with additional API. This physical separation prevents direct contact between incompatible APIs, eliminating chemical incompatibilities while maintaining the convenience of fixed-dose combination therapy
Solution Approach 2:
The capsule shell acts as an intermediary barrier between the internal and external APIs. This intermediate structure prevents direct chemical interaction between incompatible substances while allowing each API to maintain its stability and therapeutic function
3Manufacturing precision
If uniform coating is applied on oblong-shaped capsules, then surface coverage is improved, but it remains difficult to obtain uniform coating on edges or axial regions versus equatorial regions
Solution Approach 1:
The patent replaces mechanical coating systems with a gas-phase supercritical fluid deposition process. This approach eliminates the geometric limitations of liquid-based methods, as the supercritical CO2 can uniformly penetrate and deposit API on all surfaces of oblong capsules, including edges and axial regions, without requiring complex multi-angle coating mechanisms
4Stability of the object's composition
If coating is applied to increase stability, then protection from oxidation and hydrolysis is achieved, but bioavailability of one or more components may be affected
Solution Approach 1:
The patent applies different qualities to different locations: the capsule interior protects hydrophobic APIs from oxidation and hydrolysis, while the exterior coating provides targeted protection and controlled release properties for the external API. This localized quality differentiation maintains stability while preserving or enhancing bioavailability through controlled dissolution characteristics
Data Source
AI summary
Pharmaceutical compositions in unit dose form comprising capsules containing one or more first active pharmaceutical ingredient in a pharmaceutically acceptable vehicle, coated with one or more second active pharmaceutical ingredients, wherein the unit dose form is a pharmaceutical grade finished dosage form, and methods of making and using the same.